Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder

Depression Clinical Trial

Official title:

A Three-arm, Parallel Group, Multicentre, Double-blind, Randomized Controlled Trial Evaluating the Impact of GeneSight Psychotropic and Enhanced-GeneSight Psychotropic, on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02466477
• Other study ID #: EXCITE-013304-ARX1009.PTL
• Status: Completed
• Phase: Phase 4
• Start date: June 2015
• Est. completion date: September 2019

Study information

• Verified date: April 2020
• Source: Assurex Health Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evidence exists supporting the ability of genetic variations to influence patient drug response and side effects. Previous studies utilizing an open-label design have shown significant improvement in major depressive disorder (MDD) patient outcomes following use of the GeneSight Psychotropic (GEN) test. The first objective of this trial is to utilize a double-blinded, randomized clinical trial design to replicate previous findings of improvement in clinical outcomes in MDD subjects whose medication therapy was guided by GEN testing. Another objective is to determine the added benefit of Enhanced-GeneSight (E-GEN) compared to GEN for the pharmacogenomic guidance of treatment selections. Furthermore, this trial intends to develop an evidence-based case for the value of GEN and E-GEN to Canadian healthcare payers.

Description:

The primary objectives of this study are 1) to compare the efficacy of GEN to treatment as usual (TAU) in improving response to psychotropic treatment in outpatients suffering from a MDD and having had - within the current episode - an inadequate response to at least one psychotropic medication included in GEN; and 2) to validate the utility of the new CAMH markers and demonstrate the superior predictive capabilities and greater clinical utility of E-GEN as compared to GEN.

This study is designed as a three-arm multi-centre, double-blind (participants and raters), randomized controlled trial to compare the clinical and economic outcomes of GEN, E-GEN and TAU for patients suffering from a MDD and having had - within the current episode - an inadequate response to at least one psychotropic medication included in GEN. Participants will be randomized in a 1:1:1 ratio to each of the three treatment arms. Recruitment will be 24 months. Follow-up will be 12 months.

Subjects will complete short diagnostic interviews specific to their clinical diagnosis, basic metabolic measures (eg. blood pressure, weight), and provide buccal swab samples for genetic analysis (the unanalyzed buccal swabs and associated DNA will be biobanked). During the first visit, blood and urine samples will be required for laboratory panel screening and blood biobanking. Subjects will be monitored over a one year period and clinical measures and healthcare resource utilization will be obtained. Treating clinicians in the GEN and E-GEN arms will receive an easy to implement report providing pharmacogenomic guidance for prescribing psychotropic medications to their patients.

The study will recruit subjects from 10 sites, stratified into 2 clusters. Nine study sites altogether will form one of the two stratified clusters. CAMH will constitute the tenth study site and the second stratified cluster.The sample size required for this study was calculated using effect size estimates drawn from a previous study conducted by Hall-Flavin et al [Pharmacogenetics Genomics 2013; 23(10)]. Assuming an effect size of 0.30 in HAM-D17 score favoring the treatment group, intra class coefficient between clusters of 20%, statistical power of 90%, an alpha level of 0.05, and an expected 16.7% rate of premature discontinuation by Week 8 (primary endpoint), a total of 570 subjects (i.e., 190 per treatment arm) are required to detect the same effect in this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 542
• Est. completion date: September 2019
• Est. primary completion date: November 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older;

• Suffer from a Major Depressive Episode meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria;

• Have had an inadequate response within the current episode to at least one psychotropic treatment in GEN. Inadequate response is defined as inadequate efficacy after 6 weeks of a psychotropic treatment or discontinuation of a psychotropic treatment due to adverse events (AEs) or intolerability;

• Have each a score on the 16-item Clinician Quick Inventory of Depressive Symptomatology (QIDS-C16) and 16-item Self-Report Quick Inventory of Depressive Symptomatology (QIDS-SR16) rating scales = 11;

• Be able to understand the requirements of the study and provide written informed consent to participate in this study;

• Agree to abide by the study protocol and its restrictions and be able to complete all aspects of the study, including all visits and tests.

Exclusion Criteria:

• Patients posing a serious suicidal risk and/or in need of immediate hospitalization as judged by the Investigator;

• Patients with a diagnosis of Bipolar I or II disorder;

• Patients with a current Axis I diagnosis of:

• Delirium

• Dementia

• Amnestic and/or other cognitive disorder

• Schizophrenia or other psychotic disorder;

• Patients having experienced hallucinations, delusions, or any psychotic symptomatology within the current depressive episode or during prior depressive episodes;

• Patient is currently in an inpatient facility;

• Patients with a history of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic or euthyroid for at least 6 months;

• Patients who meet DSM-IV-TR criteria for any significant current substance use disorder;

• Patients with:

• hepatic insufficiency (three times the upper limit of normal (ULN) for aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)); liver transplant recipient; cirrhosis of the liver;

• malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications;

• significant unstable medical condition or life threatening disease with - need for therapies that may obscure the results of treatment and/or of the study;

• Participation in another clinical trial within 30 days of the screening visit;

• Anticipated inability to attend scheduled study visits;

• Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedure outlined in this protocol;

• Patients with a history of prior pharmacogenomic testing;

• Any change in psychotropic medication (including change in dosage) between screening and baseline;

• Patients currently receiving electroconvulsive therapy (ECT), deep brain stimulation (DBS) or transcranial magnetic stimulation (TMS) treatments, or currently scheduled to receive maintenance treatments of ECT, DBS, or TMS during the course of the study;

• Patients who self-report to be pregnant or lactating;

• Patients with a history of gastric bypass surgery.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Disease

Intervention

Genetic:
• GeneSight Psychotropic (GEN)
Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
• Enhanced-GeneSight Psychotropic (E-GEN)
The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.

Other:
• Treatment as Usual (TAU)
Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.

Locations

Country	Name	City	State
Canada	Chatham-Kent Clinical Trials Research Center	Chatham	Ontario
Canada	Hamilton Community Health Centre Family Health Organization	Hamilton	Ontario
Canada	Hamilton Medical Research Group	Hamilton	Ontario
Canada	St. Joseph's Healthcare Hamilton (SJHH)	Hamilton	Ontario
Canada	London Health Sciences Centre	London	Ontario
Canada	Milestone Research	London	Ontario
Canada	Parkwood Institute, London	London	Ontario
Canada	Hopital Montfort	Ottawa	Ontario
Canada	Thornhill Medical Centre	Thornhill	Ontario
Canada	Canadian Phase Onward Inc.	Toronto	Ontario
Canada	Centre for Addiction and Mental Health (CAMH)	Toronto	Ontario
Canada	Manna Research	Toronto	Ontario
Canada	Sinai Health System	Toronto	Ontario
Canada	Women's College Hospital	Toronto	Ontario

Sponsors (6)

Lead Sponsor	Collaborator
Assurex Health Inc.	Assurex Health Ltd., Centre for Addiction and Mental Health, Genome Canada, Mars Excellence in Clinical Innovation and Technology Evaluation, Programs for Assessment of Technology in Health Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in depressive symptoms as assessed by the 17-item Hamilton Depression (HAM-D17) score	Mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to Week 8 of the study	From baseline to Week 8
Secondary	Change in depressive symptoms as assessed by the 16-Item Clinician Quick Inventory of Depressive Symptomatology (QIDS-SR16)		Baseline, Weeks 8 and 12, and Month 12
Secondary	Change in depressive symptoms as assessed by the 9-Item Patient Health Questionnaire (PHQ-9)		Baseline, Weeks 8 and 12, and Month 12
Secondary	Change in anxiety symptoms as assessed by theGeneralized Anxiety Disorder 7-Item (GAD-7) Scale		Baseline, Weeks 8 and 12, and Month 12
Secondary	Change in severity of illness as assessed by the Clinical Global Impression of Severity (CGI-S)		Baseline, Week 12 and Month 12
Secondary	Change in global improvement as assessed by the Clinical Global Impression of Improvement (CGI-I)		Week 12, and Month 12
Secondary	Change in global therapeutic benefit and global severity of side effects as assessed by the Clinical Global Impression Efficacy Index		Week 12 and Month 12
Secondary	Changes to initial prescribing based on availability of pharmacogenomic data		Screening and Baseline
Secondary	Response rates to psychotropic medication	A responder is defined as a participant with 50% decrease in HAM-D17 score from baseline.	Baseline, Weeks 8 and 12, Months 6, 9 and 12
Secondary	Remission rates	A remitter is defined as a participant with HAM-D17 score equal or less that 7.	Baseline, Weeks 8 and 12, Months 6, 9 and 12
Secondary	Time to response		Baseline, Weeks 8 and 12, Months 6, 9 and 12
Secondary	Time to remission		Baseline, Weeks 8 and 12, Months 6, 9 and 12
Secondary	Change in psychotropic medication side effects as assessed by the Udvalg for Kliniske Undersogeler (UKU) Side Effect Rating Scale		Baseline, Weeks 8 and 12, and Month 12
Secondary	Change in global measure of side effects (frequency, intensity, and burden domains) as assessed by the Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER)		Baseline, Weeks 8 and 12, and Month 12
Secondary	Weight gain	Subject's weight	Baseline, Weeks 8 and 12, and Month 12
Secondary	Waist-to-hip ratio	Subject's waist and hip measurements	Baseline, Weeks 8 and 12, and Month 12
Secondary	Change in health related quality of life as assessed by the EuroQol (EQ-5D-5L)		Baseline, Week 12, Months 6, 9 and 12
Secondary	Change in health related quality of life as assessed by the Short Form (36) Health Survey (SF-36)		Baseline, Week 12, Months 6, 9 and 12
Secondary	Pharmacogenetics in Psychiatry Follow-up Questionnaire (PIPFQ)	The PIPFQ is a questionnaire developed by CAMH to evaluate each physician's attitude and experience to pharmacogenomic testing. Information is solicited from the physician on three different domains: the processing of the physician's last referral, the contact and outcome of the physician's patient, and the physician's perspective on the future of genetic studies in psychiatric drug treatment.	Baseline, when prescription changes are made (expected average of every 4 weeks), and Month 12
Secondary	Healthcare resource utilization (Composite measure of healthcare costs): physician visits, hospital utilization, emergency department visits, medication use, and laboratory tests		Baseline, Weeks 8 and 12, Months 6, 9 and 12
Secondary	Productivity losses (measured as economic costs)		Baseline, Weeks 8 and 12, Months 6, 9 and 12